Anika Therapeutics | ANIK - Nettoeinkommen

Aktienkurs
14.76
Täglich Wechseln
-0.46 -3.02%
Monatlich
2.79%
Jährlich
8.21%
Q2 Prognose
14.36




Nettoeinkommen Veränderung Datum
Abbott USD 1.78B 132M 2025-12
Agenus USD -10.63M 74.49M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Integra LifeSciences USD -1.7M 3.7M 2025-12
J&J USD 5.12B 36M 2025-12
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Ligand Pharmaceuticals USD 117.27M 112.43M 2025-09
MacroGenics USD -14.16M 30.98M 2025-12
Merit Medical Systems USD 27.76M 4.83M 2025-09
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR -801M 3.6B 2025-12
Smith & Nephew USD 293M 79M 2025-12
Stryker USD 849M 10M 2025-12
Surmodics USD -5.32M 6.22M 2025-06
Veracyte USD 41.15M 22.01M 2025-12
Xencor USD -6.65M 626K 2025-12
Zimmer Biomet Holdings USD 139.3M 91.6M 2025-12